Back to Cell Types

HuP-T3Homo sapiens (Human)Cancer cell line

Also known as: HUPT3, HupT3, HuPT3, Hu-P-T3, HUP-T3

🤖 AI SummaryBased on 12 publications

Quick Overview

Human pancreatic carcinoma cell line with distinct metabolic and genetic profiles.

Detailed Summary

HuP-T3 is a human pancreatic carcinoma cell line established from the ascites of a 66-year-old male patient with carcinomatous peritonitis. It exhibits a population doubling time of 38.6 hours and is capable of forming tumors in mice. The cell line shows characteristics of poorly differentiated adenocarcinoma when implanted in nude mice. HuP-T3 is keratin-positive, indicating its epithelial origin, and expresses CEA but not CA19-9. It has been used in studies examining the biological and biochemical characteristics of pancreatic cancer, including metabolic profiling and genetic alterations. The cell line has also been utilized in research on the role of cell surface markers and intermediate filaments in tumor biology.

Research Applications

Metabolic profilingGenetic alterations analysisTumor biology studiesCell surface marker analysisIntermediate filament characterization

Key Characteristics

Keratin-positive (epithelial origin)CEA positive, CA19-9 negativePoorly differentiated adenocarcinoma when implantedTumorigenic in micePopulation doubling time of 38.6 hours

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1299
Species	Homo sapiens (Human)
Tissue Source	Ascites[UBERON:UBERON_0007795]

Donor Information

Age	66
Age Category	Adult
Sex	Male
Race	asian

Disease Information

Disease	Pancreatic adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	DSMZ
Source ID	ACH-000118_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg282Trp (c.844C>T)	Unspecified	-	PubMed=21173094, PubMed=1373872
MutationSimple	MSH6	p.Lys1358fs*2 (c.4071_4072insGATT)	Heterozygous	-	Unknown, Unknown
MutationSimple	KRAS	p.Gly12Arg (c.34G>C)	Unspecified	-	PubMed=26124327

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

10

D13S317

9,11

D16S539

10,13

D18S51

16,17

D19S433

13,16

D21S11

28,30

D2S1338

19,25

D3S1358

15,16

D5S818

10,14

D7S820

12

D8S1179

15

FGA

21,22

Penta D

9,10

Penta E

16,17

TH01

9

TPOX

8,12

vWA

18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.

Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.

Oncogene 24:1794-1801(2005).

Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.

Veltman J.A., van Kessel A.G., Hoglund M.

Cancer Res. 64:3052-3059(2004).

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

Newly established human pancreatic carcinoma cell lines and their lectin binding properties.

Yamazaki K., Watanabe A., Sasaki H.

Int. J. Pancreatol. 13:31-41(1993).

Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.

Saeger H.-D.

Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013).